Provista Diagnostics., a provider of oncology-based diagnostic tests and clinical laboratory services, has opened a 13,611-sq.-ft. laboratory. The newly remodeled facility, located in Scottsdale, AZ will house the Provista Dx Reference Laboratory, a CLIA accredited laboratory that is also GLP compliant.

Provista develops and commercializes proprietary blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. Through the Provista Dx Reference Laboratory, the company will offer a wide range of clinical diagnostic services, in addition to contract research and biopharma testing to clients throughout the U.S. According to Provista, the new Laboratory, which is secured on a long-term lease, is both larger and superior to the site that it currently utilizes and provides a platform for further expansion of the services that can be offered. The new facility, which is both CLIA-accredited and GLP capable, is licensed in 45 states to perform human clinical testing and will offer a comprehensive menu of testing services, including custom projects.

“The move to this state-of-the-art facility clearly demonstrates the level of commitment that Provista is making to our customers and to the level of recent investments made in the company,” said Dr. David Reese, President and CEO of Provista Diagnostics, Inc.

With the opening of the new facility, Provista has hired Dr. Sherri Borman, Ph.D., HCLD/CC as its Clinical Laboratory Director. Dr. Borman will be responsible for all clinical laboratory functions in the Provista Dx Reference Laboratory, including quality control, methodologies and certification. She is board certified both as a High-complexity Clinical Laboratory Director (HCLD) and a Clinical Consultant (CC) through the American Board of Bioanalysis (ABB) along with a Technical Supervisor (TS) board certification in Embryology, Andrology and Endocrinology.